Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: Synthesizing results across different research designs

Journal of Clinical Psychiatry

Volumn 74, Issue 6, 2013, Pages 568-575

  Kirson, Noam Y ^a   Weiden, Peter J ^b   Yermakov, Sander ^a   Huang, Wayne ^a   Samuelson, Thomas ^a   Offord, Steve J ^c   Greenberg, Paul E ^a   Wong, Bruce J O ^d  

^a ANALYSIS GROUP   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CLOPENTHIXOL; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ARTICLE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; META ANALYSIS; METHODOLOGY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84879595485     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12r08167     Document Type: Article

References (37)

1. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry. 1999;46(10):1396-1408. doi:10.1016/S06-323(9)059-1 PubMed
2. Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract. 2010;16(5):306-324. doi:10.1097/01.pra.038626.9862.a0 PubMed
3. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419-429. doi:10.1093/schbul/21.3.419 PubMed
4. Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The Expert Consensus Guideline Series: Adherence Problems in Patients With Serious and Persistent Mental Illness. J Clin Psychiatry. 2009;70(suppl 4):1-46, quiz 47-48. doi:10.408/JCP.7090su1cj PubMed
5. Olivares JM, Rodriguez-Morales A, Diels J, et al; e-STAR Spanish Study Group. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287-296. doi:10.1016/j.eurpsy.208.12.02 PubMed
6. Haddad P, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry. 2009;195:s20-s28. doi:10.192/bjp.195.52.s20
7. Rosenheck RA, Krystal JH, Lew R, et al; CSP555 Research Group. Longacting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851. doi:10.1056/NEJMoa105987 PubMed
8. Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603-609. doi:10.176/api.ajp.201.108124 PubMed
9. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92. doi:10.1016/j.schres. 2010.1.020 PubMed
10. Mohamed S, Rosenheck R, Harpaz-Rotem I, et al. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr Q. 2009;80(4):241-249. doi:10.107/s126-09-91-9 PubMed
11. Barnett PG, Scott JY, Krystal JH, et al; CSP 555 Research Group. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2012;73(5):696-702. doi:10.408/JCP.1m07070 PubMed
12. French JRP. Field experiments: changing group productivity. In: Miller JG, ed. Experiments in Social Process: A Symposium on Social Psychology. New York, NY: McGraw-Hill; 1950: 79-96.
13. Droitcour J, Silberman G, Chelimsky E. A new form of meta-analysis for combining results from randomized clinical trials and medical-practice databases. Int J Technol Assess Health Care. 1993;9(3):440-449. doi:10.1017/S026462304694 PubMed
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. doi:10.1016/0197-2456(86)9046-2 PubMed
15. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30(1):67-76. doi:10.1093/epirev/mxn01 PubMed
16. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141. doi:10.1371/journal.pmed.020141 PubMed
17. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64(1): 19-28. doi:10.101/archpsyc.64.1.19 PubMed
18. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247. doi:10.101/archpsyc.56.3.241 PubMed
19. Mortensen PB, Eaton WW. Predictors for readmission risk in schizophrenia. Psychol Med. 1994;24(1):223-232. doi:10.1017/S032917026982 PubMed
20. Ciudad A, Haro JM, Alonso J, et al. The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain. Eur Psychiatry. 2008;23(1):1-7. doi:10.1016/j.eurpsy.207.09.08 PubMed
21. Kozma CM, Weiden PJ. Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database. Am Health Drug Benefits. 2009;2(1):31-38.
22. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560 [review]. doi:10.136/bmj.327.7414.57 PubMed
23. Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351(9096):123-127. doi:10.1016/S0140-6736(97)08468-7 PubMed
24. Macfadden W, Ma YW, Thomas Haskins J, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010;7(11):23-31. PubMed
25. Gaebel W, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-2377. doi:10.1038/np.2010.1 PubMed
26. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24- week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181-189. doi:10.176/api.ajp. 209.0708121 PubMed
27. Keks NA, Ingham M, Khan A, et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007;191(2):131-139. doi:10.192/bjp.bp.105.017020 PubMed
28. Kim B, Lee SH, Choi TK, et al. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1231-1235. doi:10.1016/j.pnpbp. 208.03.012 PubMed
29. Zhu B, Ascher-Svanum H, Shi L, et al. Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. Psychiatr Serv. 2008;59(3):315-317. doi:10.176/api.ps.59.3.315 PubMed
30. Emsley R, Oosthuizen P, Koen L, et al. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12):2378-2386. doi:10.1016/j.clinthera.208.12.020 PubMed
31. Tiihonen J, Wahlbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224. doi:10.136/bmj.381. 38275.2F PubMed
32. Tavcar R, Dernovsek MZ, Zvan V. Choosing antipsychotic maintenance therapy - a naturalistic study. Pharmacopsychiatry. 2000;33(2):66-71. doi:10.105/s-20-7969 PubMed
33. Sackett DL, Wennberg JE. Choosing the best research design for each question. BMJ. 1997;315(7123):1636. doi:10.136/bmj.315.7123.1636 PubMed
34. del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics. 1975;16(1):32-36. PubMed
35. Johnson DA. The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand. 1976;53(4):298-301. PubMed
36. Hogarty GE, Schooler NR, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry. 1979;36(12):1283-1294. doi:10.101/archpsyc.1979.017801201301 PubMed
37. Johnson DA. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry. 1979;135(6):524-530. doi:10.192/bjp.135.6.524 PubMed